Toxicokinetic/Toxicodynamic Interaction Studies in Rats between the Drugs of Abuse γ-Hydroxybutyric Acid and Ketamine and Treatment Strategies for Overdose
Open Access
- 18 May 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (5) , 741
Abstract
γ-hydroxybutyric acid (GHB) is widely abused alone and in combination with other club drugs such as ketamine. GHB exhibits nonlinear toxicokinetics, characterized by saturable metabolism, saturable absorption and saturable renal reabsorption mediated by monocarboxylate transporters (MCTs). In this research, we characterized the effects of ketamine on GHB toxicokinetics/toxicodynamics (TK/TD) and evaluated the use of MCT inhibition and specific receptor antagonism as potential treatment strategies for GHB overdose in the presence of ketamine. Adult male Sprague-Dawley rats were administered GHB 600 mg/kg i.v. alone or with ketamine (6 mg/kg i.v. bolus plus 1 mg/kg/min i.v. infusion). Plasma and urine samples were collected and respiratory parameters (breathing frequency, tidal and minute volume) continuously monitored using whole-body plethysmography. Ketamine co-administration resulted in a significant decrease in GHB total and metabolic clearance, with renal clearance remaining unchanged. Ketamine prevented the compensatory increase in tidal volume produced by GHB, and this resulted in a significant decline in minute volume when compared to GHB alone. Sleep time and lethality were also increased after ketamine co-administration when compared to GHB. L-lactate and AR-C155858 (potent MCT inhibitor) treatment resulted in an increase in GHB renal and total clearance and improvement in respiratory depression. AR-C155858 administration also resulted in a significant decrease in GHB brain/plasma ratio. SCH50911 (GABAB receptor antagonist), but not naloxone, improved GHB-induced respiratory depression in the presence of ketamine. In conclusion, ketamine ingestion with GHB can result in significant TK/TD interactions. MCT inhibition and GABAB receptor antagonism can serve as potential treatment strategies for GHB overdose when it is co-ingested with ketamine.Keywords
Funding Information
- National Institute on Drug Abuse (DA-023223)
This publication has 47 references indexed in Scilit:
- Brain Uptake of the Drug of Abuse γ-Hydroxybutyric Acid in RatsDrug Metabolism and Disposition, 2012
- Concentration-Effect Relationships for the Drug of Abuse γ-Hydroxybutyric AcidThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Monocarboxylate Transporter-Mediated Transport of γ-Hydroxybutyric Acid in Human Intestinal Caco-2 CellsDrug Metabolism and Disposition, 2010
- AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7–10Biochemical Journal, 2010
- HCN1 Channel Subunits Are a Molecular Substrate for Hypnotic Actions of KetamineThe Journal of Neuroscience, 2009
- Effects of L-Lactate and D-Mannitol on γ-Hydroxybutyrate Toxicokinetics and Toxicodynamics in RatsDrug Metabolism and Disposition, 2008
- Cataleptic effects of γ-hydroxybutyrate (GHB) and baclofen in mice: mediation by GABAB receptors, but differential enhancement by N-methyl-d-aspartate (NMDA) receptor antagonistsPsychopharmacology, 2008
- High-Risk Behaviors and Hospitalizations Among Gamma Hydroxybutyrate (GHB) UsersThe American Journal of Drug and Alcohol Abuse, 2007
- Transport of γ-Hydroxybutyrate in Rat Kidney Membrane Vesicles: Role of Monocarboxylate TransportersThe Journal of Pharmacology and Experimental Therapeutics, 2006
- A Tale of Novel Intoxication: Seven Cases of γ-Hydroxybutyric Acid OverdoseAnnals of Emergency Medicine, 1998